Bio News

Ildong Pharmaceutical will acquire 7,097,016 redeemable convertible preferred shares in its affiliate Idience for 36.755 billion won.
Ildong Pharmaceutical decided to make the investment to strengthen strategic ties among its new drug pipeline assets.
After the acquisition, Ildong Pharmaceutical will hold a 13.95% stake in Idience and may exercise a put option against Ildong Holdings, Idience’s largest shareholder.

Biobook Team
biobookmedia@biobook.co.krDaewoong Pharmaceutical’s Flodicitinib Achieves More Than 90% Target Occupancy in Phase 1 Trial
Aribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug